News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
230 Results
Type
Article (2)
Company Profile (1)
Press Release (227)
Section
Business (39)
Drug Development (33)
FDA (28)
Job Trends (5)
News (108)
Policy (12)
Tag
Academia (1)
Alliances (13)
Approvals (28)
Best Places to Work (5)
Cardiovascular disease (5)
Clinical research (35)
Data (7)
Diabetes (3)
Earnings (7)
Events (18)
FDA (30)
GLP-1 (2)
Healthcare (21)
Job creations (3)
Legal (3)
Metabolic disorders (5)
NextGen: Class of 2025 (1)
Obesity (4)
People (13)
Pharmaceutical (1)
Phase II (5)
Phase III (26)
Pipeline (5)
Postmarket research (5)
Real estate (4)
Regulatory (11)
Women's health (1)
Date
Last 30 days (1)
Last 365 days (10)
2025 (10)
2024 (10)
2023 (5)
2022 (1)
2021 (8)
2020 (11)
2019 (15)
2018 (8)
2017 (15)
2016 (27)
2015 (6)
2014 (16)
2013 (17)
2012 (13)
2011 (12)
2010 (23)
Location
Europe (12)
New Jersey (16)
New York (1)
United States (17)
230 Results for "novonordiskus".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
Press Releases
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
November 27, 2025
·
6 min read
Business
Novo Nordisk to present new data from key diabetes and obesity trials at the 60th Annual Meeting of the European Association for the Study of Diabetes
September 6, 2024
·
5 min read
Press Releases
Novo Nordisk’s CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
November 7, 2025
·
8 min read
Press Releases
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
November 6, 2025
·
12 min read
Press Releases
Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
October 21, 2025
·
10 min read
Press Releases
FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
October 20, 2025
·
12 min read
Press Releases
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress
June 23, 2025
·
8 min read
Press Releases
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
June 9, 2025
·
6 min read
Press Releases
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
March 31, 2025
·
6 min read
1 of 23
Next
